FDA Gives Thumbs-Up to Enhertu for Hard-to-Treat HER2+ Breast Cancer | BioSpace

Specifically, it was approved for adults with unresectable or metastatic HER2-positive breast cancer who have had two or more previous anti-HER2-based treatments in the metastatic setting.

Read the full article here

Related Articles